Hereditary Hemorrhagic Telangiectasia
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Hereditary Hemorrhagic Telangiectasia is an emerging landscape with 24 programs across 18 companies. The most active players are Terremoto Biosciences Inc., Karuna Therapeutics, Inc., a Bristol Myers Squibb company, Alnylam Pharmaceuticals. 2 therapies are approved with 3 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Terremoto Biosciences Inc.
1 program
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
1 program
Alnylam Pharmaceuticals
1 program
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
1 program
Sun Pharma
1 program
Bristol-Myers Squibb
1 program
Pipeline
Programs by Phase
Analysis
Modality Breakdown
84%
Small molecule
21 of 25 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 25 classified programs, each share of the total. Modality classified for 93% of 28 pipeline programs.
Analysis
Trial Status
31
clinical trials
Clinical Trials
Trial Activity
31 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)